This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Thursday, July 7, 2011
Anadys enrollment completed in the Phase IIb study of setrobuvir (ANA598)
Anadys Pharmaceuticals, Inc. (the "Company") is reporting that enrollment has been completed in the Phase IIb study of setrobuvir (ANA598), in which setrobuvir is being tested in combination with pegylated interferon and ribavirin in hepatitis C patients. The Company anticipates that all patients in the study will have completed their 12 week visit by the end of the third quarter of 2011 and plans to release preliminary 12 week data shortly thereafter.
No comments:
Post a Comment